Plasma KIM-1 and interleukin-18 are superior biomarkers for diagnosing and stratifying risk in type 1 acute cardiorenal syndrome
DOI:
https://doi.org/10.15584/ejcem.2025.2.22Keywords:
acute cardiorenal syndrome, AHF, AKI, IL-18, KIM-1Abstract
Introduction and aim. Acute cardiorenal syndrome (CRS) is a condition in which acute cardiac dysfunction leads to acute kidney injury (AKI), resulting in high morbidity and mortality rates. This study aimed to assess the diagnostic and prognostic value of plasma kidney injury molecule 1 (KIM-1) and interleukin-18 (IL-18) levels in acute CRS compared to acute heart failure (AHF) and healthy controls.
Material and methods. A case-control study was conducted with 90 participants divided into three groups: control (n=30), AHF (n=30), and acute CRS (n=30). Renal function parameters (serum creatinine, blood urea nitrogen, estimated glomerular filtration rate) and plasma biomarkers (KIM-1, IL-18) were measured. A receiver operating characteristic curve analysis was used to evaluate diagnostic performance and logistic regression was used to identify predictors of disease outcomes.
Results. Plasma KIM-1 and IL-18 levels were significantly higher in the acute CRS group than in the AHF and control groups. KIM-1 demonstrated superior diagnostic accuracy (the area under the curve (AUC)=1.000) with 100% sensitivity and specificity, while IL-18 also performed well (AUC=0.96, sensitivity=96%, specificity=97%). ROC analysis identified plasma KIM-1 and IL-18 cut-off values of >72.78 pg/mL and >254.8 pg/mL, respectively, which may be used as thresholds for early diagnosis and risk stratification. Logistic regression analysis revealed that plasma KIM-1 was a significant predictor of adverse outcomes (OR=3.5, 95% CI 1.50–8.49, p=0.003), while IL-18 also contributed to risk stratification (OR=1.06, 95% CI 1.04–1.125, p=0.03). These adverse outcomes included progression to kidney disease. However, these findings require validation in an independent cohort to confirm reproducibility and generalizability.
Conclusion. KIM-1 and IL-18 are highly effective biomarkers for diagnosing and stratifying the risk of acute CRS, outperforming traditional markers of renal function. Their clinical integration could enable early detection and personalized treatment, thus improving patient outcomes. However, more studies with larger cohorts, serial measurements, and independent validation are warranted.
Downloads
References
Kha ndait H, Sodhi S, Khandekar N, Bhattad VB. Cardiorenal syndrome in heart failure with preserved ejection fraction: insights into pathophysiology and recent advances. CardioRenal Med. 2025;1:1-40. doi: 10.1159/000542633
Tandel S, Mishra A, Jain S, et al. Impact of acute kidney injury in patients with acute decompensated heart failure: Cardiorenal syndrome. Indonesian Journal of Cardiology. 2023;44(2):75-86. doi: 10.30701/ijc.1561
Watanabe Y, Inoue T, Nakano S, Okada H. Prognosis of Patients with Acute Kidney Injury due to Type 1 Cardiorenal Syndrome Receiving Continuous Renal Replacement Therapy. Cardiorenal Med. 2023;13(1):158-166. doi: 10.1159/000527111
Xu C, Tsihlis G, Chau K, Trinh K, Rogers NM, Julovi SM. Novel perspectives in chronic kidney disease-specific cardiovascular disease. Int J Mol Sci. 2024;25(5). doi: 10.3390/ijms25052658
Savira F, Magaye R, Liew D, et al. Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculature. Br J Pharmacol. 2020;177(13):2906–2922. doi: 10.1111/bph.15065.
Lisa A, Carbone F, Liberale L, Montecucco F. The need to identify novel markers for early renal injury in cardiorenal syndrome. Cells. 2024;13(15):1283. doi: 10.3390/cells13151283
Spencer S, Desborough R, Bhandari S. Should cystatin C eGFR become routine clinical practice? Biomolecules. 2023;13(7):1075. doi: 10.3390/biom13071075
Cottam D, Azzopardi G, Forni LG. Biomarkers for early detection and predicting outcomes in acute kidney injury. Br J Hosp Med. 2022;83(8):1-11. doi: 10.12968/hmed.2022.0032
Erdil N. Cardiovascular disease, signaling, gene/cell therapy and advanced nanobiomaterials. Adv Biol Earth Sci. 2024;9:58. doi: 10.62476/abes9s58
Claure-Del Granado R, Chávez-Íñiguez JS. Renal biomarkers in cardiovascular patients with acute kidney injury: A case report and literature review. Diagnostics. 2023;13(11):1922. doi: 10.3390/diagnostics13111922
Mahmoud MA, Reyad E, Essily KE, Hanna DRK, Awady HE. The use of tissue markers of kidney injury KIM-1 and NAG to compare the effect of extracorporeal shock wave lithotripsy and retrograde intrarenal surgery on renal tissue for early detection of kidney injury in managing renal stone ≤2 cm. QJM. 2024;117(2). doi: 10.1093/qjmed/hcae175.277
Alentov I, Karmakova T, Savchina V, Dyoshkina T, Marshutina N. Kim-1 is a marker of nephrotoxicity in patients receiving cisplatin-containing chemotherapy. Cardiometry. 2023;(29):8-9. doi: 10.18137/cardiometry.2023.29.conf.1
Shaker AM, Mohamed MF, Thabet KK, Ramzy T, Abdelhamid YM. Serum interleukin-18, kidney injury molecule-1, and the renal resistive index for predicting acute kidney injury in critically ill patients with sepsis. Saudi J Kidney Dis Transpl. 2023;34(1):S153-S160. doi: 10.4103/sjkdt.sjkdt_56_22
Farooq M, Shafi M, Rafiq A, Ullah I, Rehman N, Rahman S. Comparison of urinary interleukin-18 as a biomarker of acute kidney injury with routine markers in intensive care units of tertiary care hospitals of Peshawar. J Med Sci. 2024;32(2):180-184. doi: 10.52764/jms.24.32.2.12
Josa Laorden C, Rubio Gracia J, Sánchez Marteles M, et al. Elevated urinary kidney injury molecule 1 (KIM-1) at discharge strongly predicts early mortality following an episode of acute decompensated heart failure. Polish Arch Intern Med. 2022;132(9):16284. doi: 10.20452/pamw.16284
Nuñez FIN, Vera MDF, Auqui LFC, et al. Biomarkers and therapeutic interventions for cardiorenal syndrome: A literature review. Int J Med Sci Dent Health. 2024;10(04):97-115. doi: 10.55640/ijmsdh-10-04-30
Cepoi M-R, Duca ST, Chetran A, et al. Chronic kidney disease associated with ischemic heart disease: To what extent do biomarkers help? Life. 2023;14(1):34. doi: 10.3390/life14010034
Shrestha B, Dunn L. The declaration of Helsinki on medical research involving human subjects: A review of the seventh revision. 2019. doi: 10.33314/jnhrc.v17i4.1042
Gail MH, Haneuse S. Power and sample size for case-control studies. In: Handbook of Statistical Methods for Case-Control Studies. Chapman and Hall/CRC; 2018:163-188.
Mitsas AC, Elzawawi M, Mavrogeni S, et al. Heart failure and cardiorenal syndrome: A narrative review on pathophysiology, diagnostic and therapeutic regimens-from a cardiologist’s view. J Clin Med. 2022;11(23):7041. doi: 10.3390/jcm11237041
Baumgartner H, De Backer J. The ESC clinical practice guidelines for the management of adult congenital heart disease 2020. Oxford University Press; 2020. doi: 10.1093/eurheartj/ehaa701
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-c184. doi: 10.1159/000339789
Silverman MP. Exact statistical distribution of the body mass index (BMI): Analysis and experimental confirmation. Open J Stat. 2022;12(3):324-356. doi: 10.4236/ojs.2022.123022
Bredy C, Ministeri M, Kempny A, et al. New York Heart Association (NYHA) classification in adults with congenital heart disease: Relation to objective measures of exercise and outcome. Eur Heart J Qual Care Clin Outcomes. 2018;4(1):51-58. doi: 10.1093/ehjqcco/qcx031
Rychik J, Ayres N, Cuneo B, et al. American Society of Echocardiography guidelines and standards for performance of the fetal echocardiogram. J Am Soc Echocardiogr. 2004;17(7):803-810. doi: 10.1016/j.echo.2004.04.011
O’Meara E, Chong KS, Gardner RS, Jardine AG, Neilly JB, McDonagh TA. The Modification of Diet in Renal Disease (MDRD) equations provide valid estimations of glomerular filtration rates in patients with advanced heart failure. Eur J Heart Fail. 2006;8(1):63-67. doi: 10.1016/j.Ejheart.2005.04.013
George D, Mallery P. IBM SPSS Statistics 26 Step by Step: A Simple Guide and Reference. Routledge; 2019. doi: 10.4324/9780429056765
Tanwar P, Naagar M, Malik G, et al. Relationship between right heart failure and cardiorenal syndrome: A review. World Journal of Biology Pharmacy and Health Sciences. 2023;13(01):122-137. doi: 10.30574/wjbphs.2023.13.1.0011
Colombo M, McGurnaghan SJ, Blackbourn LA, et al. Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. Diabetologia. 2020;63:788-798. doi: 10.1007/s00125-019-05081-8
Quiroga B, Díez J. Estimation of glomerular filtration rate in cardiorenal patients: A step forward. Oxford University Press. 2023:1049-1055. doi: 10.1093/ckj/sfad083
Zeng D, Wang B, Xiao Z, et al. Early diagnosis and treatment of kidney injury: A focus on urine protein. Int J Mol Sci. 2024;25(20):11171. doi: 10.3390/ijms252011171.
Koyner JL. Assessment and diagnosis of renal dysfunction in the ICU. Chest. 2012;141(6):1584-1594. doi: 10.1378/chest.11-1513
Islam MS, Ara MI, Rahman MHA, et al. Superiority of admission blood urea nitrogen over serum creatinine in predicting in-hospital outcome of patients with acute coronary syndrome. Cardiovasc J. 2022;14(2):135-142. doi: 10.3329/cardio.v14i2.58778
Jourde-Chiche N, Burtey S. Accumulation of protein-bound uremic toxins: The kidney remains the leading culprit in the gut-liver-kidney axis. Kidney Int. 2020;97(6):1102-1104. doi: 10.1016/j.kint.2020.02.026
Liu T, Liu Q, Qi H, et al. Early diagnostic value of KIM-1, NGAL, and NLR in acute kidney injury caused by diquat poisoning. J Clin Pharm Ther. 2023;2023(1):8213247. doi: 10.1155/2023/8213247
Thomas JM, Huuskes BM, Sobey CG, Drummond GR, Vinh A. The IL-18/IL-18R1 signalling axis: Diagnostic and therapeutic potential in hypertension and chronic kidney disease. Pharmacol Ther. 2022;239. doi: 10.1016/j.pharmthera.2022.108191
Mossalem AM, M Abdelgeleel N, Elaal MFA, Abdelgawad MI, Zeid AESA. Role of IL-18 in comparison to serum creatinine in early detection of sepsis-induced acute kidney injury in the emergency department at Suez Canal University Hospital. J Adv Med Med Res. 2022;34(21):121-129. doi: 10.9734/jammr/2022/v34i2131530
Zhang T, Widdop RE, Ricardo SD. Transition from acute kidney injury to chronic kidney disease: Mechanisms, models, and biomarkers. Am J Physiol Renal Physiol. 2024;327(5):F788-F805. doi: 10.1152/ajprenal.00184.2024
Siew ED. Do novel biomarkers have utility in the diagnosis and prognosis of AKI?: Commentary. Kidney360. 2023;4(12):1670-1671. doi: 10.34067/kid.0000000000000240
Novick D. IL-18 and IL-18BP: A unique dyad in health and disease. Int J Mol Sci. 2024;25(24):13505. doi: 10.3390/ijms252413505
Miyazawa H, Wada T. Immune-mediated inflammatory diseases with chronic excess of serum interleukin-18. Front Immunol. 2022;13:930141. doi: 10.3389/fimmu.2022.930141
Vecchie A, Bonaventura A, Toldo S, Dagna L, Dinarello CA, Abbate A. IL-18 and infections: Is there a role for targeted therapies? J Cell Physiol. 2021;236(3):1638-1657. doi: 10.1002/jcp.30008
Larstorp ACK, Salvador CL, Svensvik BA, Klingenberg O, Distante S. Neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C are early biomarkers of acute kidney injury associated with cardiac surgery. Scand J Clin Lab Invest. 2022;82(5):410-418. doi: 10.1080/00365513.2022.2114105
Hua Y, Zhang W, Li X. The value of soluble ST2 in predicting cardiorenal syndrome type 1 in acute myocardial infarction patients. Heart Surg Forum. 2023. doi: 10.59958/hsf.6669
Sisodiya SM. Precision medicine and therapies of the future. Epilepsia. 2021;62(2):S90-S105. doi: 10.1111/epi.16539
Bakker E, Starokozhko V, Kraaijvanger JW, Heerspink HJ, Mol PG. Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020. Clin Transl Sci. 2023;16(11):2394-2412. doi: 10.1111/cts.13641
Kubrak T, Podgórski R, Aebisher D, Gala-Błądzińska A. The significance of NGAL and KIM-1 proteins for diagnosis of acute kidney injury (AKI) in clinical practice. Eur J Clin Exp Med. 2018;(1):28-33. doi: 10.15584/ejcem.2018.1.4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
